Stopping dupilumab in controlled severe asthma
Part of Immune system & allergy, Lungs & breathing clinical trials.
This trial tests whether patients with well-controlled severe asthma can safely stop taking dupilumab after at least 3 years of treatment. If you qualify, you may be able to stop the medication and see if your asthma stays under control.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have been taking dupilumab for severe asthma for at least 3 years.
- Your asthma is well controlled, meaning you have few symptoms and had no more than 1 asthma attack in the last year.
- You are not currently smoking.
- You are not pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether dupilumab can help people with moderate-to-severe asthma achieve clinical remission. It may be an option if you have asthma with high levels of certain inflammatory markers and have had at least one asthma attack in the last 2 years.
This study tests a new way to monitor severe asthma that is driven by high levels of inflammation (T2-high). It involves a bronchoscopy (a thin tube to look inside your lungs) to see how well the treatment is working.
This study looks at how well and how safely the medicine Dupilumab works for children whose asthma is not well-controlled with their current inhalers. The goal is to see if it can help reduce asthma attacks and improve daily life.
This study tests whether dupilumab improves how well mucus is cleared from the airways in adults with moderate to severe asthma. It may help find better ways to reduce mucus-related breathing problems in people with a specific asthma type.
This study looks at how well dupilumab works over time for people with COPD who still have symptoms despite standard treatments and who have a certain type of inflammation (elevated eosinophils). It uses data from regular doctor visits and patient questionnaires to understand real-world benefits and safety.
This study looks at whether children with well-controlled eczema can safely reduce how often they take Dupixent. It aims to find the lowest effective dose to keep eczema under control.
Hear when a new Severe Asthma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.